EXAS

EXAS

USD

Exact Sciences Corporation Common Stock

$69.590-0.480 (-0.685%)

Precio en Tiempo Real

Healthcare
Diagnostics & Research
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$70.070

Máximo

$72.810

Mínimo

$67.970

Volumen

1.54M

Fundamentos de la Empresa

Capitalización de Mercado

13.2B

Industria

Diagnostics & Research

País

United States

Estadísticas de Negociación

Volumen Promedio

2.95M

Bolsa

NCM

Moneda

USD

Rango de 52 Semanas

Mínimo $38.81Actual $69.590Máximo $72.83

Noticias Relacionadas

Analyst Upgrades

TD Cowen Maintains Buy on Exact Sciences, Raises Price Target to $90

TD Cowen analyst Dan Brennan maintains Exact Sciences with a Buy and raises the price target from $74 to $90.

Ver más
TD Cowen Maintains Buy on Exact Sciences, Raises Price Target to $90
Analyst Upgrades

Baird Maintains Outperform on Exact Sciences, Raises Price Target to $88

Baird analyst Catherine Schulte maintains Exact Sciences with a Outperform and raises the price target from $72 to $88.

Ver más
Baird Maintains Outperform on Exact Sciences, Raises Price Target to $88
Analyst Upgrades

Benchmark Maintains Buy on Exact Sciences, Raises Price Target to $75

Benchmark analyst Bruce D. Jackson maintains Exact Sciences with a Buy and raises the price target from $60 to $75.

Ver más
Benchmark Maintains Buy on Exact Sciences, Raises Price Target to $75
Analyst Upgrades

Guggenheim Maintains Buy on Exact Sciences, Raises Price Target to $75

Guggenheim analyst Subbu Nambi maintains Exact Sciences with a Buy and raises the price target from $70 to $75.

Ver más
Guggenheim Maintains Buy on Exact Sciences, Raises Price Target to $75
Analyst Upgrades

Barclays Maintains Overweight on Exact Sciences, Raises Price Target to $77

Barclays analyst Luke Sergott maintains Exact Sciences with a Overweight and raises the price target from $65 to $77.

Ver más
Barclays Maintains Overweight on Exact Sciences, Raises Price Target to $77
Analyst Upgrades

Stifel Maintains Buy on Exact Sciences, Raises Price Target to $80

Stifel analyst Daniel Arias maintains Exact Sciences with a Buy and raises the price target from $67 to $80.

BusinessWire

Exact Sciences to Participate in November Investor Conference

Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate